The global medical aesthetics market, valued at US$15.59 billion in 2023, is forecasted to grow at a robust CAGR of 12.8%, reaching US$17.16 billion in 2024 and an impressive US$35.32 billion by 2030.

The global medical aesthetics market, valued at US$15.59 billion in 2023, is forecasted to grow at a robust CAGR of 12.8%, reaching US$17.16 ...

The U.S. dermal fillers market thrives with hyaluronic acid driving demand, projecting a 36% CAGR due to rising popularity of injectables and cosmetic treatment Ankush Nikam Future Market Insights, ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. If you ...

As a trusted companion for first-time moms, Cetaphil Baby recently held an intimate and educational event aimed at building ...

The report furnishes an intricate comprehension of each segment, delivering potential estimations for principal applications and insights into emerging prospects. Every regional market is meticulously ...

The US Food and Drug Administration (FDA) has approved Galderma's monoclonal antibody, Nemluvio (nemolizumab), for ...

Switzerland’s Galderma has won US Food and Drug Administration (FDA) approval for the use of Nemluvio (nemolizumab) for ...

This highly anticipated drug is expected to become a key treatment for prurigo nodularis and atopic dermatitis. Galderma’s midterm targets for the period 2023 to 2027 are for low- to mid-teens ...

The FDA has blessed two previously approved medicines—one a cream and the other an injection—to treat atopic dermatitis (AD).

The hyperpigmentation disorder treatment market is gaining traction globally due to the rising prevalence of skin conditions, increasing awareness of advanced treatment options, and growing focus on ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to ...